The directorate-general of anti-dumping and allied duties (DGAD) has recommended imposition of provisional anti-dumping duty on all imports of Vitamin A Palmitate exported from European Union and Georgia. It has also recommended provisional anti-dumping duty on Vitamin C III on all imports from USA and Canada.

In its preliminary findings, the DGAD concluded that these products were being exported by the above mentioned countries to India below normal value, resulting in dumping and resulting material injury to the Indian industry.

For Vitamin A Palmitate, the DGAD has said that the anti-dumping duty has to be the difference between US $ 113.84 per kg and landed value of import. In the case of Vitamin C III, it is the difference between US $ 10.11 and landed value of imports per kg. The DGAD investigations against the alleged anti-dumping were carried out after the petitions from Nicholas Piramal India Ltd and Ambalal Sarabhai Enterprises.

However, anti-dumping duty were not recommended in the case of Vitamin A Palmitate imports from Singapore and Vitamin C III imports from Taiwan. While these are provisional duties, the DGAD has, till date, imposed final anti-dumping duties on 20 cases involving pharmaceutical products.

They are Bisphenol A - I (Japan), Isobutyl Benzene (IBB) - I (China), Theophylline and Caffeine - I (China), 8 - Hydroxy Quinoline (China), Bisphenol - A - III (USA), Vitamin C I (Japan & China), Lovastatin (China), Ortho Chloro Benzaldehyde (China), Metronidazole (China), Vitamin C II (Russia & EU), Pthalic Anhydride (Indonesia), Hydroxyl Amine Sulphate (USA, Japan, EU), Theophylline & Caffeine - II (EU), Analgin (China & Taiwan), Paracetamol (China & Taiwan), Vitamin AD3 - I (EU & Singapore), Diclofenac Sodium (China), Trimethoprim - II (China), Vitamin AB2D3K (EU, Thailand & Singapore) and Vitamin AD3 - II (China).